These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34837061)

  • 1. TP0586532, a non-hydroxamate LpxC inhibitor, has in vitro and in vivo antibacterial activities against Enterobacteriaceae.
    Fujita K; Takata I; Yoshida I; Okumura H; Otake K; Takashima H; Sugiyama H
    J Antibiot (Tokyo); 2022 Feb; 75(2):98-107. PubMed ID: 34837061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP0586532, a Novel Non-Hydroxamate LpxC Inhibitor: Potentiating Effect on
    Yoshida I; Takata I; Fujita K; Takashima H; Sugiyama H
    Microbiol Spectr; 2022 Jun; 10(3):e0082822. PubMed ID: 35647694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic target assessment and prediction of clinically effective dosing regimen of TP0586532, a novel non-hydroxamate LpxC inhibitor, using a murine lung infection model.
    Fujita K; Takata I; Yoshida I; Honma Y; Okumura H; Otake K; Takashima H; Sugiyama H
    J Infect Chemother; 2022 May; 28(5):635-642. PubMed ID: 35131156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP0586532, a non-hydroxamate LpxC inhibitor, reduces LPS release and IL-6 production both in vitro and in vivo.
    Fujita K; Takata I; Yoshida I; Takashima H; Sugiyama H
    J Antibiot (Tokyo); 2022 Mar; 75(3):136-145. PubMed ID: 34987187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532.
    Ushiyama F; Takashima H; Matsuda Y; Ogata Y; Sasamoto N; Kurimoto-Tsuruta R; Ueki K; Tanaka-Yamamoto N; Endo M; Mima M; Fujita K; Takata I; Tsuji S; Yamashita H; Okumura H; Otake K; Sugiyama H
    Bioorg Med Chem; 2021 Jan; 30():115964. PubMed ID: 33385955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
    Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N
    J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity.
    Yamada Y; Takashima H; Walmsley DL; Ushiyama F; Matsuda Y; Kanazawa H; Yamaguchi-Sasaki T; Tanaka-Yamamoto N; Yamagishi J; Kurimoto-Tsuruta R; Ogata Y; Ohtake N; Angove H; Baker L; Harris R; Macias A; Robertson A; Surgenor A; Watanabe H; Nakano K; Mima M; Iwamoto K; Okada A; Takata I; Hitaka K; Tanaka A; Fujita K; Sugiyama H; Hubbard RE
    J Med Chem; 2020 Dec; 63(23):14805-14820. PubMed ID: 33210531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens.
    Tomaras AP; McPherson CJ; Kuhn M; Carifa A; Mullins L; George D; Desbonnet C; Eidem TM; Montgomery JI; Brown MF; Reilly U; Miller AA; O'Donnell JP
    mBio; 2014 Sep; 5(5):e01551-14. PubMed ID: 25271285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.
    Jackman JE; Fierke CA; Tumey LN; Pirrung M; Uchiyama T; Tahir SH; Hindsgaul O; Raetz CR
    J Biol Chem; 2000 Apr; 275(15):11002-9. PubMed ID: 10753902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
    Zhang J; Zhang L; Li X; Xu W
    Curr Med Chem; 2012; 19(13):2038-50. PubMed ID: 22414079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis.
    Barb AW; Zhou P
    Curr Pharm Biotechnol; 2008 Feb; 9(1):9-15. PubMed ID: 18289052
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Monogue ML; Giovagnoli S; Bissantz C; Zampaloni C; Nicolau DP
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Captopril potentiated meropenem activity against MBL-producing carbapenem-resistant Klebsiella pneumoniae: in vitro and in vivo study.
    Zhao D; Li H; Yue C; Sun K; Dai Y; Zhang H; Liu Y; Gao Y; Li J
    J Inorg Biochem; 2021 May; 218():111381. PubMed ID: 33647540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel Inhibitors of LpxC Displaying Potent in Vitro Activity against Gram-Negative Bacteria.
    Surivet JP; Panchaud P; Specklin JL; Diethelm S; Blumstein AC; Gauvin JC; Jacob L; Masse F; Mathieu G; Mirre A; Schmitt C; Lange R; Tidten-Luksch N; Gnerre C; Seeland S; Herrmann C; Seiler P; Enderlin-Paput M; Mac Sweeney A; Wicki M; Hubschwerlen C; Ritz D; Rueedi G
    J Med Chem; 2020 Jan; 63(1):66-87. PubMed ID: 31804826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, structure, and antibiotic activity of aryl-substituted LpxC inhibitors.
    Liang X; Lee CJ; Zhao J; Toone EJ; Zhou P
    J Med Chem; 2013 Sep; 56(17):6954-6966. PubMed ID: 23914798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria.
    Liu F; Ma S
    Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of potent Gram-negative specific LpxC inhibitors.
    Mansoor UF; Vitharana D; Reddy PA; Daubaras DL; McNicholas P; Orth P; Black T; Siddiqui MA
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1155-61. PubMed ID: 21273067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial activities and characterization of novel inhibitors of LpxC.
    Clements JM; Coignard F; Johnson I; Chandler S; Palan S; Waller A; Wijkmans J; Hunter MG
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1793-9. PubMed ID: 12019092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial polymers as therapeutics for treatment of multidrug-resistant Klebsiella pneumoniae lung infection.
    Lou W; Venkataraman S; Zhong G; Ding B; Tan JPK; Xu L; Fan W; Yang YY
    Acta Biomater; 2018 Sep; 78():78-88. PubMed ID: 30031912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
    Cuny GD
    Expert Opin Ther Pat; 2009 Jun; 19(6):893-9. PubMed ID: 19473108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.